Exploring US High Growth Tech Stocks To Watch In June 2025
Over the last 7 days, the United States market has remained flat, yet it is up 11% over the past year with earnings expected to grow by 15% per annum over the next few years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an evolving market landscape.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Super Micro Computer |
26.38% |
39.09% |
★★★★★★ |
|
Mereo BioPharma Group |
53.64% |
66.60% |
★★★★★★ |
|
Alvotech |
23.69% |
50.61% |
★★★★★★ |
|
Ardelyx |
21.03% |
60.42% |
★★★★★★ |
|
TG Therapeutics |
26.46% |
38.75% |
★★★★★★ |
|
AVITA Medical |
27.42% |
61.05% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
23.63% |
60.61% |
★★★★★★ |
|
Alkami Technology |
20.53% |
76.67% |
★★★★★★ |
|
Ascendis Pharma |
35.07% |
59.92% |
★★★★★★ |
|
Lumentum Holdings |
22.99% |
103.97% |
★★★★★★ |
Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener.
We’ll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Exelixis, Inc. is an oncology-focused company dedicated to discovering, developing, and commercializing new medicines for challenging cancer treatments in the United States, with a market cap of approximately $11.83 billion.
Operations: The company generates revenue primarily through the discovery, development, and commercialization of medicines targeting difficult-to-treat cancers, amounting to $2.30 billion.
Exelixis has demonstrated robust growth in the biotech sector with its recent earnings surge by 213.9% over the past year, significantly outpacing the industry average of 21.7%. This growth is underpinned by a strategic focus on R&D, evidenced by their latest successful phase 3 trial results for zanzalintinib, enhancing their portfolio in oncology treatments. The company’s forward-looking R&D investment aligns with its revenue and earnings forecasts, which are set to outperform the US market projections of 8.8% and 14.6%, respectively. Additionally, Exelixis’s commitment to innovation is further highlighted by its recent FDA approval for CABOMETYX®, expanding treatment options in neuroendocrine tumors and reinforcing its market position through scientific advancement and targeted therapy solutions.
Simply Wall St Growth Rating: ★★★★★☆
Overview: BeOne Medicines Ltd. is an oncology company focused on discovering and developing cancer treatments globally, with a market cap of $30.55 billion.
Operations: BeOne Medicines Ltd. generates revenue primarily from its pharmaceutical products, totaling $4.18 billion.
BeOne Medicines recently showcased compelling clinical data at the EHA Congress, underlining its leadership in hematologic oncology with promising results from its BCL2 and BTK inhibitors. With a 96% overall response rate and 52% complete responses reported for sonrotoclax in CLL/SLL treatments, BeOne is advancing these therapies into Phase 3 trials. This progress reflects BeOne’s strategic R&D investments, which are pivotal to its goal of redefining care standards in B-cell malignancies, positioning the company at the forefront of next-generation cancer therapies.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Circle Internet Group, Inc. operates as a platform, network, and market infrastructure for stablecoin and blockchain applications with a market cap of $59.97 billion.
Operations: Circle Internet Group generates revenue primarily through its data processing segment, amounting to $1.89 billion.
Circle Internet Group, recently added to the S&P Global BMI Index, has been dynamically expanding its footprint in the digital finance sector. The company’s strategic collaboration with Fiserv to develop stablecoin-enabled solutions underscores its innovative approach in leveraging blockchain technology for financial applications. This partnership is poised to enhance payment experiences and operational efficiencies across banks and fintech platforms, reflecting Circle’s commitment to driving forward the integration of traditional financial systems with digital economies. With a recent IPO raising $1.054 billion and collaborations that bridge gaps between digital and fiat currencies, Circle is positioning itself as a pivotal player in shaping future financial infrastructures.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EXEL ONC and CRCL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com